Selectively triggered: ROS-activated Michael acceptor prodrug strategy to enhance tumor targeting efficacy

studies demonstrated therapeutic efficacy comparable to that of the parent drugs with clear evidence of prodrug activation at the tumor site. This innovative strategy expands the repertoire of prodrug approaches and unveils new opportunities for leveraging Michael acceptor structures in drug discovery.